DOCSLIB.ORG

Table S3. E-Genes Comprising the Seven Main GO Categories

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Table S3. E-Genes Comprising the Seven Main GO Categories Table S3. E-genes comprising the seven main GO categories representative of the frontier at a %5 FDR Entrez Gene q- S-gene GO term GB# Gene Name LLR sign Gene Symbol value conn. ectoderm development 1490 AA598794 CTGF connective tissue growth factor 0.0105 78.32 GLS -1 ectoderm development 1308 AA128561 COL17A1 collagen, type XVII, alpha 1 0.0241 30.90 TFDP1 1 ectoderm development 1290 AA857098 COL5A2 collagen, type V, alpha 2 0.0373 27.36 SCN5A -1 ectoderm development 3910 N94616 LAMA4 laminin, alpha 4 0.0019 19.57 TFDP1 -1 ectoderm development 1281 T98612 COL3A1 collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant) 0.0378 19.23 SCN5A -1 ectoderm development 3918 AA677534 LAMC2 laminin, gamma 2 0.0241 16.07 TFDP1 1 ectoderm development 5629 AA932629 PROX1 prospero-related homeobox 1 0.0241 15.10 SCN5A 1 ectoderm development 3858 AA428454 KRT10 keratin 10 (epidermolytic hyperkeratosis; keratosis palmaris et plantaris) 0.0352 13.37 SCN5A 1 ectoderm development 5351 AA476240 PLOD1 procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1 0.0241 12.54 SCN5A -1 ectoderm development 5493 AI680568 PPL periplakin 0.0241 12.12 SCN5A 1 ectoderm development 1281 T98612 COL3A1 collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant) 0.0310 11.83 KRT20 -1 ectoderm development 7042 N45138 TGFB2 transforming growth factor, beta 2 0.0534 8.19 SCN5A 1 ectoderm development 1718 AI057612 DHCR24 24-dehydrocholesterol reductase 0.0241 7.29 UBE2L6 -1 ectoderm development 1999 AA433851 ELF3 E74-like factor 3 (ets domain transcription factor, epithelial-specific ) 0.0241 5.98 SCN5A 1 ectoderm development 1638 AA478553 DCT dopachrome tautomerase (dopachrome delta-isomerase, tyrosine-related protein 2) 0.0242 4.78 SCN5A 1 ectoderm development 2012 AA975768 EMP1 epithelial membrane protein 1 0.0339 4.10 SCN5A 1 ectoderm development 3860 W60057 KRT13 keratin 13 0.0280 3.27 SCN5A -1 ectoderm development 7357 AA165628 UGCG UDP-glucose ceramide glucosyltransferase 0.0394 2.56 ADAM21 -1 ectoderm development 5493 AI126713 PPL periplakin 0.0241 2.45 SCN5A 1 ectoderm development 5493 AA454209 PPL periplakin 0.0241 2.32 SCN5A 1 ectoderm development 404786 T60075 FABP5 fatty acid binding protein 5 (psoriasis-associated) 0.0506 2.28 SCN5A -1 ectoderm development 3713 AI417983 IVL involucrin 0.0967 1.51 SCN5A 1 ectoderm development 6699 AA447835 SPRR1B small proline-rich protein 1B (cornifin) 0.0262 0.87 SCN5A 1 ectoderm development 51535 R52965 PPHLN1 periphilin 1 0.0503 0.49 KRT20 -1 excision repair cross-complementing rodent repair deficiency, complementation group ectoderm development 2068 R05503 ERCC2 0.0241 0.19 SCN5A -1 2 (xeroderma pigmentosum D) carboxylic acid transport 6509 AI131128 SLC1A4 solute carrier family 1 (glutamate/neutral amino acid transporter), member 4 0.0140 56.90 UBE2L6 1 carboxylic acid transport 6506 AA775980 SLC1A2 solute carrier family 1 (glial high affinity glutamate transporter), member 2 0.0029 37.92 TFDP1 -1 carboxylic acid transport 8604 H16761 SLC25A12 solute carrier family 25 (mitochondrial carrier, Aralar), member 12 0.0143 29.81 TFDP1 -1 carboxylic acid transport 6576 AA676877 SLC25A1 solute carrier family 25 (mitochondrial carrier; citrate transporter), member 1 0.0244 25.94 UBE2L6 -1 carboxylic acid transport 54407 R27457 SLC38A2 solute carrier family 38, member 2 0.0242 22.29 SCN5A 1 aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3- carboxylic acid transport 1645 R96610 AKR1C1 0.0104 18.68 CCR9 1 alpha)-hydroxysteroid dehydrogenase) carboxylic acid transport 54407 AA081106 SLC38A2 solute carrier family 38, member 2 0.0246 18.28 SCN5A 1 solute carrier family 3 (activators of dibasic and neutral amino acid transport), member carboxylic acid transport 6520 AA630794 SLC3A2 0.0242 17.79 SCN5A 1 2 carboxylic acid transport 6509 AA598625 SLC1A4 solute carrier family 1 (glutamate/neutral amino acid transporter), member 4 0.0241 17.60 SCN5A 1 carboxylic acid transport 6507 AA453823 SLC1A3 solute carrier family 1 (glial high affinity glutamate transporter), member 3 0.0729 15.62 SCN5A -1 carboxylic acid transport 57709 AA992065 KIAA1613 KIAA1613 protein 0.0676 14.06 DHX32 1 carboxylic acid transport 10630 AA046430 T1A-2 lung type-I cell membrane-associated glycoprotein 0.0019 12.78 TFDP1 -1 carboxylic acid transport 81539 AA449481 SLC38A1 solute carrier family 38, member 1 0.0303 9.73 SCN5A 1 carboxylic acid transport 117247 W32409 SLC16A10 solute carrier family 16 (monocarboxylic acid transporters), member 10 0.0235 8.77 TFDP1 -1 carboxylic acid transport 8140 AA419177 SLC7A5 solute carrier family 7 (cationic amino acid transporter, y+ system), member 5 0.0242 7.65 SCN5A 1 carboxylic acid transport 81539 R66556 SLC38A1 solute carrier family 38, member 1 0.0241 5.81 SCN5A 1 carboxylic acid transport 10166 AA035452 SLC25A15 solute carrier family 25 (mitochondrial carrier; ornithine transporter) member 15 0.0241 5.38 SCN5A -1 carboxylic acid transport 81539 R45292 SLC38A1 solute carrier family 38, member 1 0.0256 4.84 SCN5A 1 carboxylic acid transport 6541 R28280 SLC7A1 solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 0.0241 4.45 SCN5A 1 aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3- carboxylic acid transport 1645 R93124 AKR1C1 0.0677 3.03 SCN5A 1 alpha)-hydroxysteroid dehydrogenase) carboxylic acid transport 9123 AA129777 SLC16A3 solute carrier family 16 (monocarboxylic acid transporters), member 3 0.0241 2.06 SCN5A 1 carboxylic acid transport 81539 AA452816 SLC38A1 solute carrier family 38, member 1 0.0241 1.65 SCN5A 1 carboxylic acid transport 10166 N76599 SLC25A15 solute carrier family 25 (mitochondrial carrier; ornithine transporter) member 15 0.0363 1.01 SCN5A 1 carboxylic acid transport 9122 R73003 SLC16A4 solute carrier family 16 (monocarboxylic acid transporters), member 4 0.0241 0.42 SCN5A 1 negative regulation of 2619 AA292054 GAS1 growth arrest-specific 1 0.0241 21.81 SCN5A 1 mitotic cell cycle negative regulation of 2296 AA495846 FOXC1 forkhead box C1 0.0241 12.36 SCN5A 1 mitotic cell cycle negative regulation of 322 H28119 APBB1 amyloid beta (A4) precursor protein-binding, family B, member 1 (Fe65) 0.0246 9.30 SCN5A -1 mitotic cell cycle negative regulation of 323 W80706 APBB2 amyloid beta (A4) precursor protein-binding, family B, member 2 (Fe65-like) 0.0241 8.52 GLS 1 mitotic cell cycle negative regulation of 7040 R36467 TGFB1 transforming growth factor, beta 1 (Camurati-Engelmann disease) 0.0241 7.50 SCN5A 1 mitotic cell cycle negative regulation of 9787 AA262211 DLG7 discs, large homolog 7 (Drosophila) 0.0098 7.38 UBE2L6 -1 mitotic cell cycle negative regulation of 5119 N27227 PCOLN3 procollagen (type III) N-endopeptidase 0.0241 7.26 SCN5A -1 mitotic cell cycle negative regulation of 4088 AI074534 SMAD3 SMAD, mothers against DPP homolog 3 (Drosophila) 0.0510 4.48 SCN5A 1 mitotic cell cycle negative regulation of 9787 W93717 DLG7 discs, large homolog 7 (Drosophila) 0.0241 4.29 SCN5A -1 mitotic cell cycle response to biotic stimulus 4600 AA286908 MX2 myxovirus (influenza virus) resistance 2 (mouse) 0.0000 216.65 CCR9 1 response to biotic stimulus 4599 AA456886 MX1 myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (mouse) 0.0000 144.18 NARG1 1 response to biotic stimulus 23586 AA126958 DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 0.0000 119.94 CCR9 1 response to biotic stimulus 91543 T95113 RSAD2 radical S-adenosyl methionine domain containing 2 0.0090 92.81 CCR9 1 response to biotic stimulus 9636 AA406020 G1P2 interferon, alpha-inducible protein (clone IFI-15K) 0.0000 72.35 CCR9 1 response to biotic stimulus 4938 AA146773 OAS1 2',5'-oligoadenylate synthetase 1, 40/46kDa 0.0000 54.51 CCR9 1 response to biotic stimulus 5788 H74265 PTPRC protein tyrosine phosphatase, receptor type, C 0.0241 34.66 TFDP1 -1 response to biotic stimulus 6387 AI655374 CXCL12 chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 0.0099 25.69 KRT20 -1 response to biotic stimulus 5359 N25945 PLSCR1 phospholipid scramblase 1 0.0241 14.85 SCN5A 1 response to biotic stimulus 5359 AI049711 PLSCR1 phospholipid scramblase 1 0.0241 13.83 SCN5A 1 response to biotic stimulus 3669 AA479795 ISG20 interferon stimulated gene 20kDa 0.0241 11.43 TFDP1 1 response to biotic stimulus 7852 T62491 CXCR4 chemokine (C-X-C motif) receptor 4 0.0241 9.02 SCN5A 1 response to biotic stimulus 2268 AA256231 FGR Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog 0.0241 8.55 SCN5A -1 response to biotic stimulus 23586 AA682834 DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 0.0310 8.55 SCN5A 1 response to biotic stimulus 5610 AA010079 EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2 0.0241 8.15 ADAM21 1 response to biotic stimulus 664 AA010383 BNIP3 BCL2/adenovirus E1B 19kDa interacting protein 3 0.0645 7.18 KRT20 -1 response to biotic stimulus 6356 W69211 CCL11 chemokine (C-C motif) ligand 11 0.0262 6.91 SCN5A -1 response to biotic stimulus 85363 H04279 TRIM5 tripartite motif-containing 5 0.0241 2.21 SCN5A 1 steroid metabolic process 51141 AA045308 INSIG2 insulin induced gene 2 0.0219 160.20 SEC24D 1 steroid metabolic process 6342 AA664009 SCP2 sterol carrier protein 2 0.0241 75.32 EIF2AK2 1 steroid metabolic process 6646 AI139693 SOAT1 sterol O-acyltransferase (acyl-Coenzyme A: cholesterol acyltransferase) 1 0.0038 52.95 TFDP1 -1 steroid metabolic process 57016 AI301329 AKR1B10 aldo-keto reductase family 1, member B10 (aldose reductase) 0.0407 52.87 GNAI3 1 steroid
Load more

Recommended publications
  • Analysis of Trans Esnps Infers Regulatory Network Architecture
    Analysis of trans eSNPs infers regulatory network architecture Anat Kreimer Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2014 © 2014 Anat Kreimer All rights reserved ABSTRACT Analysis of trans eSNPs infers regulatory network architecture Anat Kreimer eSNPs are genetic variants associated with transcript expression levels. The characteristics of such variants highlight their importance and present a unique opportunity for studying gene regulation. eSNPs affect most genes and their cell type specificity can shed light on different processes that are activated in each cell. They can identify functional variants by connecting SNPs that are implicated in disease to a molecular mechanism. Examining eSNPs that are associated with distal genes can provide insights regarding the inference of regulatory networks but also presents challenges due to the high statistical burden of multiple testing. Such association studies allow: simultaneous investigation of many gene expression phenotypes without assuming any prior knowledge and identification of unknown regulators of gene expression while uncovering directionality. This thesis will focus on such distal eSNPs to map regulatory interactions between different loci and expose the architecture of the regulatory network defined by such interactions. We develop novel computational approaches and apply them to genetics-genomics data in human. We go beyond pairwise interactions to define network motifs, including regulatory modules and bi-fan structures, showing them to be prevalent in real data and exposing distinct attributes of such arrangements. We project eSNP associations onto a protein-protein interaction network to expose topological properties of eSNPs and their targets and highlight different modes of distal regulation.
    [Show full text]
  • Genome-Wide DNA Methylation Profiling Identifies Differential Methylation in Uninvolved Psoriatic Epidermis
    Genome-Wide DNA Methylation Profiling Identifies Differential Methylation in Uninvolved Psoriatic Epidermis Deepti Verma, Anna-Karin Ekman, Cecilia Bivik Eding and Charlotta Enerbäck The self-archived postprint version of this journal article is available at Linköping University Institutional Repository (DiVA): http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-147791 N.B.: When citing this work, cite the original publication. Verma, D., Ekman, A., Bivik Eding, C., Enerbäck, C., (2018), Genome-Wide DNA Methylation Profiling Identifies Differential Methylation in Uninvolved Psoriatic Epidermis, Journal of Investigative Dermatology, 138(5), 1088-1093. https://doi.org/10.1016/j.jid.2017.11.036 Original publication available at: https://doi.org/10.1016/j.jid.2017.11.036 Copyright: Elsevier http://www.elsevier.com/ Genome-Wide DNA Methylation Profiling Identifies Differential Methylation in Uninvolved Psoriatic Epidermis Deepti Verma*a, Anna-Karin Ekman*a, Cecilia Bivik Edinga and Charlotta Enerbäcka *Authors contributed equally aIngrid Asp Psoriasis Research Center, Department of Clinical and Experimental Medicine, Division of Dermatology, Linköping University, Linköping, Sweden Corresponding author: Charlotta Enerbäck Ingrid Asp Psoriasis Research Center, Department of Clinical and Experimental Medicine, Linköping University SE-581 85 Linköping, Sweden Phone: +46 10 103 7429 E-mail: [email protected] Short title Differential methylation in psoriasis Abbreviations CGI, CpG island; DMS, differentially methylated site; RRBS, reduced representation bisulphite sequencing Keywords (max 6) psoriasis, epidermis, methylation, Wnt, susceptibility, expression 1 ABSTRACT Psoriasis is a chronic inflammatory skin disease with both local and systemic components. Genome-wide approaches have identified more than 60 psoriasis-susceptibility loci, but genes are estimated to explain only one third of the heritability in psoriasis, suggesting additional, yet unidentified, sources of heritability.
    [Show full text]
  • TASOR Is a Pseudo-PARP That Directs HUSH Complex Assembly and Epigenetic Transposon Control
    Lawrence Berkeley National Laboratory Recent Work Title TASOR is a pseudo-PARP that directs HUSH complex assembly and epigenetic transposon control. Permalink https://escholarship.org/uc/item/6021r2cd Journal Nature communications, 11(1) ISSN 2041-1723 Authors Douse, Christopher H Tchasovnikarova, Iva A Timms, Richard T et al. Publication Date 2020-10-02 DOI 10.1038/s41467-020-18761-6 Peer reviewed eScholarship.org Powered by the California Digital Library University of California ARTICLE https://doi.org/10.1038/s41467-020-18761-6 OPEN TASOR is a pseudo-PARP that directs HUSH complex assembly and epigenetic transposon control Christopher H. Douse 1,4,9, Iva A. Tchasovnikarova2,5,9, Richard T. Timms 2,9, Anna V. Protasio 2,6, Marta Seczynska2, Daniil M. Prigozhin 1,7, Anna Albecka1,2,8, Jane Wagstaff3, James C. Williamson2, ✉ ✉ Stefan M. V. Freund3, Paul J. Lehner 2 & Yorgo Modis 1,2 1234567890():,; The HUSH complex represses retroviruses, transposons and genes to maintain the integrity of vertebrate genomes. HUSH regulates deposition of the epigenetic mark H3K9me3, but how its three core subunits — TASOR, MPP8 and Periphilin — contribute to assembly and targeting of the complex remains unknown. Here, we define the biochemical basis of HUSH assembly and find that its modular architecture resembles the yeast RNA-induced tran- scriptional silencing complex. TASOR, the central HUSH subunit, associates with RNA pro- cessing components. TASOR is required for H3K9me3 deposition over LINE-1 repeats and repetitive exons in transcribed genes. In the context of previous studies, this suggests that an RNA intermediate is important for HUSH activity. We dissect the TASOR and MPP8 domains necessary for transgene repression.
    [Show full text]
  • Noelia Díaz Blanco
    Effects of environmental factors on the gonadal transcriptome of European sea bass (Dicentrarchus labrax), juvenile growth and sex ratios Noelia Díaz Blanco Ph.D. thesis 2014 Submitted in partial fulfillment of the requirements for the Ph.D. degree from the Universitat Pompeu Fabra (UPF). This work has been carried out at the Group of Biology of Reproduction (GBR), at the Department of Renewable Marine Resources of the Institute of Marine Sciences (ICM-CSIC). Thesis supervisor: Dr. Francesc Piferrer Professor d’Investigació Institut de Ciències del Mar (ICM-CSIC) i ii A mis padres A Xavi iii iv Acknowledgements This thesis has been made possible by the support of many people who in one way or another, many times unknowingly, gave me the strength to overcome this "long and winding road". First of all, I would like to thank my supervisor, Dr. Francesc Piferrer, for his patience, guidance and wise advice throughout all this Ph.D. experience. But above all, for the trust he placed on me almost seven years ago when he offered me the opportunity to be part of his team. Thanks also for teaching me how to question always everything, for sharing with me your enthusiasm for science and for giving me the opportunity of learning from you by participating in many projects, collaborations and scientific meetings. I am also thankful to my colleagues (former and present Group of Biology of Reproduction members) for your support and encouragement throughout this journey. To the “exGBRs”, thanks for helping me with my first steps into this world. Working as an undergrad with you Dr.
    [Show full text]
  • WO 2019/079361 Al 25 April 2019 (25.04.2019) W 1P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2019/079361 Al 25 April 2019 (25.04.2019) W 1P O PCT (51) International Patent Classification: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, C12Q 1/68 (2018.01) A61P 31/18 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, C12Q 1/70 (2006.01) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/US2018/056167 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (22) International Filing Date: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 16 October 2018 (16. 10.2018) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 62/573,025 16 October 2017 (16. 10.2017) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, ΓΕ , IS, IT, LT, LU, LV, (71) Applicant: MASSACHUSETTS INSTITUTE OF MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TECHNOLOGY [US/US]; 77 Massachusetts Avenue, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Cambridge, Massachusetts 02139 (US).
    [Show full text]
  • Download Author Version (PDF)
    Molecular BioSystems Accepted Manuscript This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication. Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available. You can find more information about Accepted Manuscripts in the Information for Authors. Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the Ethical guidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains. www.rsc.org/molecularbiosystems Page 1 of 29 Molecular BioSystems Mutated Genes and Driver Pathways Involved in Myelodysplastic Syndromes—A Transcriptome Sequencing Based Approach Liang Liu1*, Hongyan Wang1*, Jianguo Wen2*, Chih-En Tseng2,3*, Youli Zu2, Chung-che Chang4§, Xiaobo Zhou1§ 1 Center for Bioinformatics and Systems Biology, Division of Radiologic Sciences, Wake Forest University Baptist Medical Center, Winston-Salem, NC 27157, USA. 2 Department of Pathology, the Methodist Hospital Research Institute,
    [Show full text]
  • Oncogenic Fusion Protein FGFR2-PPHLN1: Requirements for Biological Activation, and Efficacy of Inhibitors
    UC San Diego UC San Diego Previously Published Works Title Oncogenic fusion protein FGFR2-PPHLN1: Requirements for biological activation, and efficacy of inhibitors. Permalink https://escholarship.org/uc/item/12g996rt Journal Translational oncology, 13(12) ISSN 1936-5233 Authors Li, Fangda Meyer, April N Peiris, Malalage N et al. Publication Date 2020-12-01 DOI 10.1016/j.tranon.2020.100853 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Translational Oncology 13 (2020) 100853 Contents lists available at ScienceDirect Translational Oncology journal homepage: www.elsevier.com/locate/tranon Oncogenic fusion protein FGFR2-PPHLN1: Requirements for biological activation, and efficacy of inhibitors ⁎ Fangda Li a, April N. Meyer a, Malalage N. Peiris a, Katelyn N. Nelson a, Daniel J. Donoghue a,b, a Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA 92093-0367, USA b UCSD Moores Cancer Center and Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA 92093-0367, USA ARTICLE INFO ABSTRACT Article history: Aim of study: Chromosomal translocations such as t(10;12)(q26,q12) are associated with intrahepatic cholangiocarci- Received 2 May 2020 noma, a universally fatal category of liver cancer. This translocation creates the oncogenic fusion protein of Fibroblast Received in revised form 24 July 2020 Growth Factor Receptor 2 joined to Periphilin 1. The aims of this study were to identify significant features required for Accepted 9 August 2020 biological activation, analyze the activation of downstream signaling pathways, and examine the efficacy of the TKIs Available online xxxx BGJ398 and TAS-120, and of the MEK inhibitor Trametinib.
    [Show full text]
  • PPHLN1 Rabbit Pab
    Leader in Biomolecular Solutions for Life Science PPHLN1 Rabbit pAb Catalog No.: A17706 Basic Information Background Catalog No. The protein encoded by this gene is one of the several proteins that become sequentially A17706 incorporated into the cornified cell envelope during the terminal differentiation of keratinocyte at the outer layers of epidermis. This protein interacts with periplakin, Observed MW which is known as a precursor of the cornified cell envelope. The cellular localization 53kDa pattern and insolubility of this protein suggest that it may play a role in epithelial differentiation and contribute to epidermal integrity and barrier formation. Multiple Calculated MW alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008] Category Primary antibody Applications WB Cross-Reactivity Human, Mouse, Rat Recommended Dilutions Immunogen Information WB 1:500 - 1:2000 Gene ID Swiss Prot 51535 Q8NEY8 Immunogen Recombinant fusion protein containing a sequence corresponding to amino acids 195-255 of human PPHLN1 (NP_958846.1). Synonyms CR;HSPC206;HSPC232;PPHLN1 Contact Product Information 400-999-6126 Source Isotype Purification Rabbit IgG Affinity purification [email protected] www.abclonal.com.cn Storage Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide,50% glycerol,pH7.3. Validation Data Western blot analysis of extracts of various cell lines, using PPHLN1 antibody (A17706) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (AS014) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit (RM00020). Exposure time: 10s. Antibody | Protein | ELISA Kits | Enzyme | NGS | Service For research use only.
    [Show full text]
  • Oncogenic Fusion Protein FGFR2-PPHLN1: Requirements for Biological Activation, and Efficacy of Inhibitors ⁎ Fangda Li A, April N
    Translational Oncology 13 (2020) 100853 Contents lists available at ScienceDirect Translational Oncology journal homepage: www.elsevier.com/locate/tranon Oncogenic fusion protein FGFR2-PPHLN1: Requirements for biological activation, and efficacy of inhibitors ⁎ Fangda Li a, April N. Meyer a, Malalage N. Peiris a, Katelyn N. Nelson a, Daniel J. Donoghue a,b, a Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA 92093-0367, USA b UCSD Moores Cancer Center and Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA 92093-0367, USA ARTICLE INFO ABSTRACT Article history: Aim of study: Chromosomal translocations such as t(10;12)(q26,q12) are associated with intrahepatic cholangiocarci- Received 2 May 2020 noma, a universally fatal category of liver cancer. This translocation creates the oncogenic fusion protein of Fibroblast Received in revised form 24 July 2020 Growth Factor Receptor 2 joined to Periphilin 1. The aims of this study were to identify significant features required for Accepted 9 August 2020 biological activation, analyze the activation of downstream signaling pathways, and examine the efficacy of the TKIs Available online xxxx BGJ398 and TAS-120, and of the MEK inhibitor Trametinib. Methods: These studies examined FGFR2-PPHLN1 proteins containing a kinase-dead, kinase-activated, or WT kinase domain in comparison with analogous FGFR2 proteins. Biological activity was assayed using soft agar colony forma- tion in epithelial RIE-1 cells and focus assays in NIH3T3 cells. The MAPK/ERK, JAK/STAT3 and PI3K/AKT signaling pathways were examined for activation. Membrane association was analyzed by indirect immunofluorescence com- paring proteins altered by deletion of the signal peptide, or by addition of a myristylation signal.
    [Show full text]
  • FGF/FGFR Signaling in Health and Disease
    Signal Transduction and Targeted Therapy www.nature.com/sigtrans REVIEW ARTICLE OPEN FGF/FGFR signaling in health and disease Yangli Xie1, Nan Su1, Jing Yang1, Qiaoyan Tan1, Shuo Huang 1, Min Jin1, Zhenhong Ni1, Bin Zhang1, Dali Zhang1, Fengtao Luo1, Hangang Chen1, Xianding Sun1, Jian Q. Feng2, Huabing Qi1 and Lin Chen 1 Growing evidences suggest that the fibroblast growth factor/FGF receptor (FGF/FGFR) signaling has crucial roles in a multitude of processes during embryonic development and adult homeostasis by regulating cellular lineage commitment, differentiation, proliferation, and apoptosis of various types of cells. In this review, we provide a comprehensive overview of the current understanding of FGF signaling and its roles in organ development, injury repair, and the pathophysiology of spectrum of diseases, which is a consequence of FGF signaling dysregulation, including cancers and chronic kidney disease (CKD). In this context, the agonists and antagonists for FGF-FGFRs might have therapeutic benefits in multiple systems. Signal Transduction and Targeted Therapy (2020) 5:181; https://doi.org/10.1038/s41392-020-00222-7 INTRODUCTION OF THE FGF/FGFR SIGNALING The binding of FGFs to the inactive monomeric FGFRs will Fibroblast growth factors (FGFs) are broad-spectrum mitogens and trigger the conformational changes of FGFRs, resulting in 1234567890();,: regulate a wide range of cellular functions, including migration, dimerization and activation of the cytosolic tyrosine kinases by proliferation, differentiation, and survival. It is well documented phosphorylating the tyrosine residues within the cytosolic tail of that FGF signaling plays essential roles in development, metabo- FGFRs.4 Then, the phosphorylated tyrosine residues serve as the lism, and tissue homeostasis.
    [Show full text]
  • Mouse Pphln1 Conditional Knockout Project (CRISPR/Cas9)
    https://www.alphaknockout.com Mouse Pphln1 Conditional Knockout Project (CRISPR/Cas9) Objective: To create a Pphln1 conditional knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Pphln1 gene (NCBI Reference Sequence: NM_146062 ; Ensembl: ENSMUSG00000036167 ) is located on Mouse chromosome 15. 10 exons are identified, with the ATG start codon in exon 2 and the TAG stop codon in exon 10 (Transcript: ENSMUST00000049122). Exon 5 will be selected as conditional knockout region (cKO region). Deletion of this region should result in the loss of function of the Mouse Pphln1 gene. To engineer the targeting vector, homologous arms and cKO region will be generated by PCR using BAC clone RP23-10A16 as template. Cas9, gRNA and targeting vector will be co-injected into fertilized eggs for cKO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Mice homozygous for a gene trap allele die prior to E7.5. Exon 5 starts from about 30.01% of the coding region. The knockout of Exon 5 will result in frameshift of the gene. The size of intron 4 for 5'-loxP site insertion: 17425 bp, and the size of intron 5 for 3'-loxP site insertion: 10404 bp. The size of effective cKO region: ~712 bp. The cKO region does not have any other known gene. Page 1 of 8 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele gRNA region 5' gRNA region 3' 1 5 10 Targeting vector Targeted allele Constitutive KO allele (After Cre recombination) Legends Exon of mouse Pphln1 Homology arm cKO region loxP site Page 2 of 8 https://www.alphaknockout.com Overview of the Dot Plot Window size: 10 bp Forward Reverse Complement Sequence 12 Note: The sequence of homologous arms and cKO region is aligned with itself to determine if there are tandem repeats.
    [Show full text]
  • Figure S1. Endogenous MIR45
    Figure S1. Endogenous MIR452 and VEGFA expression in CRC tissues and cell lines. (A) The expression of MIR452 was validated using 10 CRC tissue samples and matched normal colon tissue samples. miRNA levels were normalized to colon-specific RNU48. Values are presented as the fold- change in tumor tissue relative levels (ΔΔCT) to normal tissue. (B) The relative endogenous MIR452 expression levels in six CRC cell lines. The data are presented as a fold change in HT29, Caco2, HCT116, LoVo, and SW48 cells relative to SW480 cells. This experiment was performed as two independent experiments, each carried out in triplicate. (C) MIR452 expression level analysis by qRT- PCR for MIR452 transfection efficiency in Caco2 and SW48 cells. (D) The relative endogenous VEGFA expression levels in five CRC cell lines. The data are presented as a fold change in HT29, Caco2, HCT116, or SW48 cells relative to SW480 cells. This experiment was performed three independent experiments, each carried out in duplicate. Table S1. The putative target genes of MIR452 identified and predicted by the microarray analysis from the MIR452 overexpressed cells. Symbol Definition Accession Homo sapiens acyl-CoA thioesterase 8 (ACOT8), transcript ACOT8 NM_005469.2 variant 1, mRNA. Homo sapiens ARP6 actin-related protein 6 homolog (yeast) ACTR6 NM_022496.3 (ACTR6), mRNA. ADI1 Homo sapiens acireductone dioxygenase 1 (ADI1), mRNA. NM_018269.1 Homo sapiens aftiphilin (AFTPH), transcript variant 1, AFTPH NM_203437.2 mRNA. AHNAK2 Homo sapiens AHNAK nucleoprotein 2 (AHNAK2), mRNA. NM_138420.2 Homo sapiens A kinase (PRKA) anchor protein 7 (AKAP7), AKAP7 NM_004842.2 transcript variant alpha, mRNA. Homo sapiens anaphase promoting complex subunit 13 ANAPC13 NM_015391.2 (ANAPC13), mRNA.
    [Show full text]